Tympanoplasty is the surgical treatment of Chronic Otitis Media and it aims to eradicate the middle ear disease and provide better hearing to the patient. 'Does age of the patient impact the outcome of tympanoplasty?' is a valid question concerning every otologist. The result of this study will highlight the success rate of graft uptake and hearing improvement with respect to different age groups. To determine if age of the patient is a factor influencing the success rate of Tympanoplasty based on the following parameters:-Graft Uptake, Post operative Hearing gain. A prospective observational study was conducted on 44 patients who underwent underlay Tympanoplasty for a dry central perforation with conductive hearing loss. Pure Tone Audiogram was done pre-operatively. The post-operative Pure Tone Audiogram was repeated three months after the surgery and was compared with the pre-operative PTA. The status of graft uptake was checked 3 months post-operatively. It was observed that the graft uptake rate was the least in the age group of 51-65 years and decreased when the age of the patient was 36-50 years. The graft uptake rate was the highest in patients between 18 and 35 years of age. The hearing gain was maximum when the age of the patient was between 18 and 35 years and gradually decreased as the age of the patient increased to 36-50 years and was the least when the age of the patient was between 50 and 65 years. The graft uptake rate was higher in the younger patients than the older patients. All cases show noticeable increase in hearing improvement following tympanoplasty. However, with the advancing age of the patient the post-operative hearing improvement decreased. Thus, 'age of the patient' impacts the success rate of tympanoplasty.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11890466 | PMC |
http://dx.doi.org/10.1007/s12070-024-05267-6 | DOI Listing |
Int J STD AIDS
March 2025
MAP Centre for Urban Health Solutions, St. Michael's Hospital, Toronto, ON, Canada.
BackgroundHepatitis B virus (HBV) disproportionately affects people at risk of HIV. Encounters for HIV post-exposure prophylaxis (PEP) create opportunities for HBV screening and prevention. We quantified HBV prevalence, susceptibility, and active/passive immunization use among patients seeking HIV PEP.
View Article and Find Full Text PDFEpilepsia
March 2025
University of California San Francisco Weill Institute for Neurosciences, Benioff Children's Hospital, San Francisco, California, USA.
Objective: We analyzed the long-term safety and effectiveness of fenfluramine (FFA) in patients with Dravet syndrome (DS) in an open-label extension (OLE) study after participating in randomized controlled trials (RCTs) or commencing FFA de novo as adults.
Methods: Patients with DS who participated in one of three RCTs or were 19 to 35 years of age and started FFA de novo were included. Key endpoints were: incidence of treatment-emergent adverse events (TEAEs) in the safety population, and median percentage change in monthly convulsive seizure frequency (MCSF) from the RCT baseline to end of study (EOS) in the modified intent-to-treat (mITT) population.
Dermatol Reports
February 2025
Division of Regenerative and Oncological Dermatological Surgery, Modena University Hospital.
In patients with epidermolysis bullosa (EB), surgery may be required to remove squamous cell carcinoma (SCC) of the hands or to correct pseudo-syndactyly. Dermal substitutes may represent a suitable tool to promote the healing of surgical wounds in EB. We review our experience with a collagen-elastin dermal matrix to promote surgical wound healing due to hand surgery to correct pseudo-syndactyly or SCC resection in patients affected by EB.
View Article and Find Full Text PDFJAMA Cardiol
March 2025
Department of Cardiovascular Medicine and Section on Geriatrics and Gerontology, Wake Forest University School of Medicine, Winston-Salem, North Carolina.
Importance: Excess body fat plays a pivotal role in the pathogenesis of heart failure with preserved ejection fraction (HFpEF). HU6 is a novel, controlled metabolic accelerator that enhances mitochondrial uncoupling resulting in increased metabolism and fat-specific weight loss.
Objective: To assess efficacy and safety of HU6 in reducing body weight, improving peak volume of oxygen consumption (VO2) and body composition among patients with obesity-related HFpEF.
JAMA Cardiol
March 2025
Stanford University School of Medicine, Stanford University, Stanford, California.
Importance: Outcomes in patients with diabetes after fractional flow reserve (FFR)-guided percutaneous coronary intervention (PCI) using current-generation drug-eluting stents (DES) compared with coronary artery bypass grafting (CABG) are unknown.
Objectives: To investigate the relative treatment effect of PCI vs CABG according to diabetes status with respect to major adverse cardiac and cerebrovascular events (MACCE) at 3 years and to evaluate the impact of the SYNTAX score.
Design, Setting, And Participants: This is a prespecified subgroup analysis of the FAME (Fractional Flow Reserve vs Angiography for Multivessel Evaluation) 3 trial, an investigator-initiated, randomized clinical trial conducted at 48 centers worldwide.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!